Ligandal is solving the delivery problem of complex therapies and enabling precision genetic medicine. By creating cell- and tissue-specific delivery technologies of gene therapies and gene editors such as CRISPR and mRNA, using synthetic peptides as targeting modalities, we develop and deliver therapeutic solutions for creating the next generation of targeted therapies.

By combining machine learning models, peptide chemistry, nanotechnology, and biological studies with our proven AI engine, we allow for the rapid discovery, design and development of novel peptide therapeutics and delivery systems geared for the 21st century of medicine. 

We are back by 10 years of foundational R&D efforts and 58 pending global patents.  Ligandal is the owner of one of the largest AI+peptide patent portfolios in the world.  We have locked up the discovery, development, and manufacturing of these unique targeted drug delivery peptide nanomaterials.